Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Applied Therapeutics Inc (APLT)

Applied Therapeutics Inc (APLT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,048,368
  • Shares Outstanding, K 116,356
  • Annual Sales, $ 9,990 K
  • Annual Income, $ -119,760 K
  • EBIT $ -92 M
  • EBITDA $ -90 M
  • 60-Month Beta 2.01
  • Price/Sales 103.86
  • Price/Cash Flow N/A
  • Price/Book 173.87

Options Overview Details

View History
  • Implied Volatility 185.12% ( -1.37%)
  • Historical Volatility 53.94%
  • IV Percentile 81%
  • IV Rank 53.12%
  • IV High 299.87% on 12/27/23
  • IV Low 55.08% on 06/24/24
  • Put/Call Vol Ratio 2.15
  • Today's Volume 2,672
  • Volume Avg (30-Day) 2,800
  • Put/Call OI Ratio 2.02
  • Today's Open Interest 110,434
  • Open Int (30-Day) 96,862

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.16
  • Number of Estimates 2
  • High Estimate -0.11
  • Low Estimate -0.21
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +51.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.35 +5.15%
on 10/29/24
10.62 -17.35%
on 11/11/24
-0.36 (-3.94%)
since 10/15/24
3-Month
4.55 +92.97%
on 09/16/24
10.62 -17.35%
on 11/11/24
+2.86 (+48.31%)
since 08/15/24
52-Week
1.79 +390.50%
on 11/27/23
10.62 -17.35%
on 11/11/24
+6.65 (+312.21%)
since 11/15/23

Most Recent Stories

More News
Applied Therapeutics Reports Third Quarter 2024 Financial Results

APLT : 8.85 (-1.78%)
Applied Therapeutics to Present at the 2024 UBS Global Healthcare Conference

APLT : 8.85 (-1.78%)
Why Applied Therapeutics Stock Is Skyrocketing Today

Investors are cheering good news from the FDA.

APLT : 8.85 (-1.78%)
Stocks Set to Open Higher as Investors Await U.S. Jobs Data and Fed Speak

June S&P 500 E-Mini futures (ESM24) are up +0.10%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.14% this morning as investors digested the latest U.S. inflation figures and looked ahead to remarks...

ESM24 : 5,471.89s (-0.09%)
NQM24 : 19,747.29s (-0.08%)
EL : 64.02 (-1.25%)
WBA : 8.58 (-2.61%)
RH : 316.89 (-1.84%)
MLKN : 24.06 (+0.06%)
CURV : 4.13 (+2.23%)
APLT : 8.85 (-1.78%)
T : 22.64 (+1.75%)
CCJ : 53.50 (+0.73%)
DVN : 38.64 (-1.88%)
BILL : 84.77 (-1.86%)
S&P Futures Tick Lower as Key U.S. Jobs Report Looms

March S&P 500 E-Mini futures (ESH24) are trending down -0.23% this morning as investors looked ahead to the crucial monthly U.S. nonfarm payrolls report for further clues on the timing of possible interest-rate...

ESH24 : 5,101.67s (-1.01%)
WBA : 8.58 (-2.61%)
MBLY : 15.18 (-2.00%)
AAPL : 224.73 (-1.53%)
ALL : 197.73 (+1.00%)
EDV.LN : 1,529.000 (+0.99%)
LIGHT.NA : 22.100 (+1.75%)
PTON : 7.70 (-3.75%)
APLT : 8.85 (-1.78%)
IBM : 206.16 (-1.35%)
FUSN : 21.55 (+0.14%)
PLTR : 64.28 (+8.62%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Applied Therapeutics, Inc. (NASDAQ: APLT)

/PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Applied Therapeutics, Inc. (NASDAQ: APLT) concerning possible breaches of...

APLT : 8.85 (-1.78%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Applied Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

APLT : 8.85 (-1.78%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Applied Therapeutics, Inc. (NASDAQ: APLT)

/PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Applied Therapeutics, Inc. (NASDAQ: APLT) concerning possible breaches of...

APLT : 8.85 (-1.78%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Applied Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

APLT : 8.85 (-1.78%)
Applied Therapeutics, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants

NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company...

APLT : 8.85 (-1.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Applied Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing drug candidates for unmet medical need. The company's product candidate consists of AT-001, for the treatment of Diabetic Cardiomyopathy; AT-007, for the treatment of Galactosemia and AT-003, for the treatment...

See More

Key Turning Points

3rd Resistance Point 9.88
2nd Resistance Point 9.58
1st Resistance Point 9.30
Last Price 8.85
1st Support Level 8.72
2nd Support Level 8.42
3rd Support Level 8.14

See More

52-Week High 10.62
Last Price 8.85
Fibonacci 61.8% 7.25
Fibonacci 50% 6.21
Fibonacci 38.2% 5.16
52-Week Low 1.79

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar